The global joint pain injections market size was estimated to be USD 5.48 billion in 2023 and is expected to reach at USD 14.7 billion by 2033 with a CAGR of 9.37% during the forecast period 2023-2033. Rising geriatric population, increasing prevalence of osteoarthritis & rheumatoid arthritis, growing need for affordable treatments for such conditions, surge in prevalence of obese population, rising research & development activities for the development of efficient treatment options, surge in product approvals by regulatory bodies, growing clinical trial activities, and increasing launch of advanced injections for joint pain management are some of the major factors fuelling the market growth.
Increasing launch of advanced injections for joint pain management is predicted to boost the market growth during the forecast period. For instance, in August 2021, HyLink, a single-injection Visco supplement for the treatment of knee osteoarthritis, was launched by Seikagaku Corporation and TCM Biotech International Corp. in Taiwan. The key component of this product is a cross-linked hyaluronate hydrogel created using cross-linking technology.
By Type, Hyaluronic acid injections was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the increasing awareness regarding the clinical benefits offered by hyaluronic acid injections, rising prevalence of osteoarthritis, growing launch of new products, and surge in research & development activities. For instance, in September 2021, Bioventus made an announcement regarding the updated Clinical Practice Guidelines (CPG) from the American Academy of Orthopaedic Surgeons (AAOS). According to the guidelines, high molecular weight cross-linked hyaluronic treatments, such as DUROLANE, demonstrated statistically significant improvement in specific knee osteoarthritis (OA) patients. Additionally, Platelet-rich plasma (PRP) injections is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of osteoarthritis, rising research & development activities, and growing number of clinical trials for pain management among osteoarthritis patients.
By Application, Knee & ankle was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the growing number of geriatric patients, rising demand for intra-articular injections, and increasing product approvals. For instance, in December 2021, Xalud Therapeutics disclosed that the U.S. Food and Drug Administration (FDA) has awarded fast track designation to their primary candidate, XT-150, for managing pain linked to knee osteoarthritis. Additionally, Hip joint is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of hip osteoarthritis, surge in number of accident injuries, and rising number of patients diagnosed with hip osteoarthritis.
By Distribution Channel, Drug stores & retail pharmacies was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the growing number of retail pharmacies supplying joint pain injections, and rising approvals by regulatory bodies for the marketing of new products. For instance, in March 2021, The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted manufacturing and marketing approval to SEIKAGAKU CORPORATION's JOYCLU for the treatment of osteoarthritis. Additionally, Online providers is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for joint pain solutions, increasing adoption of smart devices & easy accessibility, shift in patient preference towards online pharmacies, and surge in less expensive injections sold by internet pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of musculoskeletal disorders, growing geriatric population, rising healthcare infrastructure, surge in adoption of advanced technologies, increasing investments in research activities by leading market players, and growing product approvals. For instance, in January 2022, SKYRIZI (risankizumab-rzaa) has obtained approval from the United States Food and Drug Administration (FDA) for treating active psoriatic arthritis (PsA) in adults. It can be administered through a single injection four times a year. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising geriatric populations, growing prevalence of obesity causing joint pain, increasing demand for advanced solutions, surge in government initiatives to promote healthy lifestyle, and rising launch of innovative products. For instance, in May 2021, SEIKAGAKU Corporation and ONO PHARMACEUTICAL CO., LTD introduced JOYCLU in Japan, an intra-articular injection aimed at managing joint function.
Increasing launch of advanced injections for joint pain management is predicted to boost the market growth during the forecast period. For instance, in August 2021, HyLink, a single-injection Visco supplement for the treatment of knee osteoarthritis, was launched by Seikagaku Corporation and TCM Biotech International Corp. in Taiwan. The key component of this product is a cross-linked hyaluronate hydrogel created using cross-linking technology.
By Type, Hyaluronic acid injections was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the increasing awareness regarding the clinical benefits offered by hyaluronic acid injections, rising prevalence of osteoarthritis, growing launch of new products, and surge in research & development activities. For instance, in September 2021, Bioventus made an announcement regarding the updated Clinical Practice Guidelines (CPG) from the American Academy of Orthopaedic Surgeons (AAOS). According to the guidelines, high molecular weight cross-linked hyaluronic treatments, such as DUROLANE, demonstrated statistically significant improvement in specific knee osteoarthritis (OA) patients. Additionally, Platelet-rich plasma (PRP) injections is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of osteoarthritis, rising research & development activities, and growing number of clinical trials for pain management among osteoarthritis patients.
By Application, Knee & ankle was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the growing number of geriatric patients, rising demand for intra-articular injections, and increasing product approvals. For instance, in December 2021, Xalud Therapeutics disclosed that the U.S. Food and Drug Administration (FDA) has awarded fast track designation to their primary candidate, XT-150, for managing pain linked to knee osteoarthritis. Additionally, Hip joint is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of hip osteoarthritis, surge in number of accident injuries, and rising number of patients diagnosed with hip osteoarthritis.
By Distribution Channel, Drug stores & retail pharmacies was the highest revenue-grossing segment in the global joint pain injections market in 2022 owing to the growing number of retail pharmacies supplying joint pain injections, and rising approvals by regulatory bodies for the marketing of new products. For instance, in March 2021, The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted manufacturing and marketing approval to SEIKAGAKU CORPORATION's JOYCLU for the treatment of osteoarthritis. Additionally, Online providers is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for joint pain solutions, increasing adoption of smart devices & easy accessibility, shift in patient preference towards online pharmacies, and surge in less expensive injections sold by internet pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of musculoskeletal disorders, growing geriatric population, rising healthcare infrastructure, surge in adoption of advanced technologies, increasing investments in research activities by leading market players, and growing product approvals. For instance, in January 2022, SKYRIZI (risankizumab-rzaa) has obtained approval from the United States Food and Drug Administration (FDA) for treating active psoriatic arthritis (PsA) in adults. It can be administered through a single injection four times a year. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising geriatric populations, growing prevalence of obesity causing joint pain, increasing demand for advanced solutions, surge in government initiatives to promote healthy lifestyle, and rising launch of innovative products. For instance, in May 2021, SEIKAGAKU Corporation and ONO PHARMACEUTICAL CO., LTD introduced JOYCLU in Japan, an intra-articular injection aimed at managing joint function.
Segmentation: Joint Pain Injections Market Report 2022 - 2033
Joint Pain Injections Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Placental Tissue Matrix (PTM) Injections
- Hyaluronic Acid Injections
- Steroid Joint Injections
- Platelet-Rich Plasma (PRP) Injections
- Others
Joint Pain Injections Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Shoulder & Elbow
- Spinal Joints
- Hip Joint
- Knee & Ankle
- Others
Joint Pain Injections Market Analysis & Forecast by Distribution Channel 2022 - 2033 (Revenue USD Bn)
- Hospital Pharmacies
- Online Providers
- Drug Stores & Retail Pharmacies
Joint Pain Injections Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Joint Pain Injections Market: Type Estimates & Trend Analysis
8. Joint Pain Injections Market: Application Estimates & Trend Analysis
9. Joint Pain Injections Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Joint Pain Injections Market
12. Europe Global Joint Pain Injections Market
13. Asia Pacific Global Joint Pain Injections Market
14. Latin America Global Joint Pain Injections Market
15. MEA Global Joint Pain Injections Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Bioventus Inc.
- Abbvie Inc.
- Eli Lilly and Company
- Seikagaku Corporation
- Ferring Pharmaceuticals Inc.
- TCM Biotech International Corporation
- Pacira Biosciences (Flexion Therapeutics Inc.)
- Xalud Therapeutics
- Pfizer Inc.
- Zimmer Biomet
- Anika Therapeutics Inc.
- Teva Pharmaceuticals
- Sanofi S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 5.48 Billion |
| Forecasted Market Value ( USD | $ 14.7 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
